Great Lakes Advisors LLC Has $2.35 Million Stake in Enovis Co. (NYSE:ENOV)

Great Lakes Advisors LLC grew its position in shares of Enovis Co. (NYSE:ENOV) by 4.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 53,584 shares of the company’s stock after buying an additional 2,415 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.09% of Enovis worth $2,351,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ENOV. Amalgamated Bank lifted its holdings in Enovis by 1.0% in the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock worth $1,136,000 after purchasing an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. lifted its holdings in Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the last quarter. Arizona State Retirement System lifted its holdings in Enovis by 2.6% in the 4th quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock worth $711,000 after purchasing an additional 414 shares during the last quarter. UMB Bank n.a. lifted its holdings in Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its holdings in Enovis by 3.5% in the 4th quarter. New York State Teachers Retirement System now owns 13,538 shares of the company’s stock worth $594,000 after purchasing an additional 457 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $37.01 on Friday. The business’s fifty day moving average price is $43.32 and its two-hundred day moving average price is $43.73. Enovis Co. has a fifty-two week low of $35.14 and a fifty-two week high of $62.79. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -16.90 and a beta of 2.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million for the quarter, compared to analysts’ expectations of $555.14 million. As a group, analysts predict that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC dropped their price target on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.